Wednesday Edition

The 10^th Joint meeting of the Americas and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)

The following summarizes some of the highlights from Day 2 of MSToronto 2026.

DOT-MS discontinuation study
OPERETTA 2 results for ocrelizumab in POMS
PIRA in early- and late-onset MS
Impact of anti-CD20 on PIRA
Low rate of postpartum relapses with anti-CD20 therapy
Does EBV seronegativity preclude MS diagnosis?
Update on FENhance trials of fenebrutinib
Clinical tip of the day
Read More

MSToronto2026 – 10^th Joint ACTRIMS-ECTRIMS meeting – October 21-23, 2026

Thursday, October 22. 16:30 – 18:30

Read More

Thursday Edition

The 10^th Joint meeting of the Americas and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)

The following summarizes some of the highlights from Day 1 of MSToronto 2026.

MS risk with infectious mononucleosis
sNfL elevation postpartum
PRLs contribute to treatment failure
Update on frexalimab
Daratumumab effective in AQ4-IgG+ NMOSD
One-quarter of MS patients are untreated
Clinical tip of the day
Read More

MSToronto2026 – 10^th Joint ACTRIMS-ECTRIMS meeting – October 21-23, 2026

Wednesday, October 21. 16:30 – 18:30

Read More